Premium
The effect of growth hormone on sleep‐related cardio‐respiratory control in Prader–Willi syndrome
Author(s) -
KatzSalamon M,
Lindgren AC,
Cohen G
Publication year - 2012
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2012.02638.x
Subject(s) - medicine , heart rate , blood pressure , growth hormone treatment , growth hormone , endocrinology , ventilation (architecture) , cardiology , anesthesia , hormone , mechanical engineering , engineering
Aim: To evaluate the effects of growth hormone (GH) treatment on control of breathing, heart rate and blood pressure during sleep in Prader–Willi Syndrome (PWS). Study design: in a prospective clinical case series study, sixteen consecutive PWS patients (median age 16 months at enrolment) were followed‐up 6 months (2–32 months) after commencing GH treatment. We compared heart rate (HR), Pulse Transit Time (PTT; an index of blood pressure, BP) and ventilatory responses to standard chemostimuli (4% CO 2 and 100% O 2 ) during quiet sleep prior to and after commencing GH treatment. Results: Growth hormone treatment increased arterial oxygenation during sleep but did not significantly improve breathing stability (apnoea‐hypopnoea index remained unchanged). GH treatment did not alter ventilatory, HR and PTT chemoreceptor‐mediated responsiveness (p = 0.23–0.97) but did significantly improve the coupling between and HR and PTT, indicating that HR and BP rose (or fell) in parallel after but not before GH therapy (p = 0.01). Conclusion: Growth hormone treatment improves arterial oxygenation and cardiovascular function during sleep; these changes are not owing to improved (stronger) chemoreflex‐mediated autonomic drive.